SCHEMBL859458

SCHEMBL859458

N[C@@H](C=O)CCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL258995 1.00
SCHEMBL68935 1.00
SCHEMBL15058114 0.98 CYP2D6 (0.61)
SCHEMBL7998715 0.98 CYP2D6 (0.61)
Hydrochloric Acid SCHEMBL10636409 0.98 CYP2D6 (0.61)
Hydrochloric Acid SCHEMBL31395319 0.98 CYP2D6 (0.61)
SCHEMBL28189436 0.98 CYP2D6 (0.61)
Aminolevulinic Acid SCHEMBL2446350 0.86 GABRR1 (0.59)
SCHEMBL12019170 0.86 ENPEP (0.52)
SCHEMBL11981919 0.84 ENPEP (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220155-A1 VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2022-07-14 US disclosed
US-9840537-B2 Selective delivery molecules and methods of use AVELAS BIOSCIENCES, INC. (US) 2017-12-12 US disclosed
US-20170044214-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS ACQUISITION CORPORATION 2017-02-16 US disclosed
US-20160220707-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS ACQUISITION CORPORATION 2016-08-04 US disclosed
US-20160152670-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS ACQUISITION CORPORATION 2016-06-02 US disclosed
US-9278144-B2 Selective delivery molecules and methods of use AVELAS BIOSCIENCES, INC. (US) 2016-03-08 US disclosed
WO-2015034920-A2 GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR COMPOSITIONS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2015-03-12 WO disclosed
US-20150031852-A1 SELECTIVE DELIVERY MOLECULES AND METHODS OF USE AVELAS BIOSCIENCES, INC. (US) 2015-01-29 US disclosed
US-8575094-B2 Use of type-B lantibiotic-based compounds having antimicrobial activity NOVACTA BIOSYSTEMS LIMITED (GB) 2013-11-05 US disclosed
US-8357638-B2 Oligonucleotide library encoding randomised peptides ASTON UNIVERSITY (GB) 2013-01-22 US disclosed
US-20090264313-A1 Oligonucleotide library encoding randomised peptides ASTON UNIVERSITY (GB) 2009-10-22 US disclosed
US-20090203583-A1 Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity NOVACTA BIOSYSTEMS LIMITED (GB) 2009-08-13 US disclosed
US-7541143-B2 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples ONCOIMMUNIN, INC. (US) 2009-06-02 US disclosed
US-20080176821-A1 LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE GEORGETOWN UNIVERSITY 2008-07-24 US disclosed
US-20080103104-A1 TREATMENT OF CANCER BIPAR SCIENCES, INC. (US) 2008-05-01 US disclosed
US-20080103208-A1 INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF BIPAR SCIENCES, INC. (US) 2008-05-01 US disclosed
US-7307148-B2 Method for purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2007-12-11 US disclosed
US-20070280939-A1 Prostatic Acid Phosphatase Antigens NOTTINGHAM TRENT UNIVERSITY, THE (GB) 2007-12-06 US disclosed
US-20070243562-A1 Lectins for Analyzing Sugar Chains and Method of Using the Same SUMMIT GLYCORESEARCH CORPORATION (JP) 2007-10-18 US disclosed
US-20070231855-A1 Functional molecule and manufacturing method therefor FUJITSU LIMITED (JP) 2007-10-04 US disclosed